Back to Authors

O’Connell, Casey

Mayo Clinic

Mayo Clinic

Citations 5

P-1228. Posaconazole Oral Suspension vs. Crushed Delayed-Release Tablets: Probability of Pharmacokinetic Target Attainment with Enteral Tube Administration
Bhattarai, Nirjan , O’Connell, Casey, Robinson, John, Cole, Kristin, Johnson, Tanner M , Stevens, Ryan W W, Wieruszewski, Patrick M. , Ilges, Dan , Stevens, Ryan W.

Open Forum Infectious Diseases | January 12, 2026 | Volume: 13 | Issue: Supplement_1 | Pages: No page available

10.1093/ofid/ofaf695.1420 Get It

Abstract Background Posaconazole immediate release (IR) suspension is the standard product for enteral feeding tube (EFT) administration but has erratic pharmacokinetic behavior and results in sub satisfactory concentrations. Limited evidence suggests that the posaconazole oral delayed-release (DR) tablets may be crushed. Methods This was a retrospective cohort study of hospitalized adults who received EFT administration of posaconazole IR suspension or crushed DR tablets between 2018 and 2024. Patients were eligible if they had at least one serum concentration drawn ≥5 days after posaconazole initiation. The primary outcome was the attainment of therapeutic (≥700ng/mL for prophylaxis, ≥1,000ng/mL for treatment) serum concentration within 30 days. Secondary outcomes included time to therapeutic serum concentration, adverse drug effects, and frequency of clogged EFT. Multivariable cox proportional hazards regression was used to assess the relationship between posaconazole formulation and attainment of therapeutic concentrations while adjusting for confounding variables. Results Of the included patients, 100 received DR tablets and 48 received IR suspension. There were no significant differences in baseline characteristics or severity of illness. Among DR tablet and IR suspension recipients, 59% and 23% achieved therapeutic concentrations, respectively (p < 0.001). After adjusting for age, sex, BMI, drug interactions, posaconazole indication, malabsorptive gastrointestinal conditions, IR suspension was significantly less likely than crushed DR tablets to achieve therapeutic posaconazole concentrations within 30-days (HR 0.37, 95% CI 0.20-0.71; p < 0.003). The crushed DR tablet group required less total daily posaconazole to achieve therapeutic concentrations (400 vs 600 mg/day, p = 0.003). Clogged EFTs were more frequent in the crushed DR tablet group (27% vs 10%, p = 0.022), while no differences were observed in the occurrence of hepatotoxicity or hypokalemia. Conclusion Administration of crushed posaconazole DR tablets via EFT is more likely to attain therapeutic concentrations compared to IR suspension. The optimal technique for administering crushed DR tablets to prevent EFT complications warrants investigation. Disclosures Patrick M. Wieruszewski, PharmD, FCCM, Wolters Kluwer/UpToDate: Advisor/Consultant
Posaconazole enteral tube administration in adults: pharmacokinetic target attainment of oral suspension compared with crushed delayed-release tablet
Bhattarai, Nirjan , Stevens, Ryan W. , Ilges, Dan , Robinson, John C. , Cole, Kristin C, O’Connell, Casey, Johnson, Tanner M , Ilges, Dan , O'Connell, Casey R, Johnson, Tanner M , Stevens, Ryan W , Wieruszewski, Patrick M. , Cole, Kristin C

Journal of Antimicrobial Chemotherapy | October 9, 2025 | Volume: 81 | Issue: 1 | Pages: No page available

10.1093/jac/dkaf396 Get It

Abstract Background Posaconazole immediate release (IR) suspension is the standard product for enteral feeding tube (EFT) administration but has erratic pharmacokinetic behaviour, often resulting in subtherapeutic concentrations. Limited evidence suggests that posaconazole oral delayed-release (DR) tablets may be crushed. Methods This was a retrospective cohort study of hospitalized adults who received EFT administration of posaconazole IR suspension or crushed DR tablets between 2018 and 2024. Patients were eligible if they had at least one serum drug concentration drawn ≥5 days after posaconazole initiation. The primary outcome was attainment of therapeutic drug concentrations. Secondary outcomes included time to therapeutic serum concentration, adverse drug events, and frequency of occluded EFT. Results Of the included patients, 48 received IR suspension and 100 received DR tablets. Baseline characteristics and severity of illnesses were well balanced. Among IR suspension and crushed DR tablet recipients, 39% and 80% achieved therapeutic concentrations, respectively (P = 0.002). After adjusting for age, sex, BMI, drug interactions, posaconazole indication and malabsorptive conditions, crushed DR tablets were significantly more likely than IR suspension to achieve therapeutic posaconazole concentrations within 30 days (HR 5.22, 95% CI 2.35–11.61). Occluded EFTs were more frequent among crushed DR tablet recipients (27% versus 10%, P = 0.022), while no differences were observed in the occurrence of hepatotoxicity or hypokalaemia. Conclusions With EFT administration, crushed posaconazole DR tablets were associated with a greater likelihood of achieving therapeutic concentrations compared with IR suspension. The optimal technique for administering crushed DR tablets to prevent EFT complications warrants investigation.
Therapeutic drug monitoring following crushed administration of delayed-release posaconazole tablets via enteral feeding tubes
Stevens, Ryan W. , O’Connell, Casey, Huang, Angie, Epps, Kevin , Ilges, Dan , Epps, Kevin L, Stevens, Ryan W , Ilges, Dan

Journal of Antimicrobial Chemotherapy | December 22, 2022 | Volume: 78 | Issue: 2 | Pages: 553-555

10.1093/jac/dkac427 Get It

Evaluation of Piperacillin-Tazobactam for Antibiotic Prophylaxis in Traumatic Grade III Open Fractures
O’Connell, Casey, Kooda, Kirstin , Sawyer, Mark D. , Wise, Kevin B., Mara, Kristin C. , Skrupky, Lee P. , O'Connell, Casey R, Kooda, Kirstin J, Mara, Kristin C , Skrupky, Lee P

Surgical Infections | October 6, 2021 | Volume: 23 | Issue: 1 | Pages: 41-46

10.1089/sur.2021.122 Get It

1765: EVALUATION OF PIPERACILLIN-TAZOBACTAM FOR ANTIBIOTIC PROPHYLAXIS IN TRAUMATIC GRADE 3 OPEN FRACTURES
O’Connell, Casey, Kooda, Kirstin , Wise, Kevin B., Sawyer, Mark D. , Skrupky, Lee P. , Mara, Kristin C.

Critical Care Medicine | December 18, 2019 | Volume: 48 | Issue: 1 | Pages: 857-857

10.1097/01.ccm.0000649356.48443.24 Get It